참고문헌
- The Korean Association for the Study of the Liver. White Paper on Liver Diseases in Korea. 2013. Available from http://www.kasl.org/bbs/index.html?code=ency&category=&gubun=&idx=&page=1&number=55&mode=view&order=&sort=&keyfield=&key=. Accessed January 16, 2018.
- Kim MS. Modification of Emergency Status in Deceased Donor Liver Allocation: Evidence for Korean Model of End-stage Liver Disease (MELD) System. J Korean Soc Transplant 2016; 30(2):51-8. https://doi.org/10.4285/jkstn.2016.30.2.51
- Lim Y-S. Acute liver failure in Korea: etiology, prognosis and treatment. Korean J Hepatol 2010; 16(1):5-18.
- Lee HJ. Liver Transplantation in Liver Cirrhosis. CMH 2006;12(20): 85-9.
- Korean Network for Organ Sharing. Guidance on organ transplant management in 2016. Available from https://www.konos.go.kr/konosis/common/bizlogic.jsp. Accessed January 16, 2018.
- Korean Network for Organ Sharing. Statistics of Organ Transplantation Cases. Available from https://www.konos.go.kr/konosis/sub4/sub-04_03_01_pop.jsp. Accessed January 16, 2018.
- The Korean Association for the Study of the Liver. Clinical Guideline for liver Cirrhosis: Ascites and other complications. 2017. Available from http://www.kasl.org/bbs/index.html?code=guide&cate-gory=&gubun=&idx=&page=1&number=3358&mode=view &order=&sort=&keyfield=&key=. Accessed on January 16, 2018.
- Healthcare Bigdata Hub. Available from http://opendata.hira.or.kr/home.do. Accessed January 16, 2018.
- Chhatwal J, Kanwal F, Roberts MS, et al. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med 2015; 162(6):397-406. https://doi.org/10.7326/M14-1336
- Cure S, Guerra I, Dusheiko G. Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients. J Viral Hepat 2015; 22(11):882-9. https://doi.org/10.1111/jvh.12409
- Leleu H, Blachier M, Rosa I. Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C. J Viral Hepat 2015; 22(4):376-83. https://doi.org/10.1111/jvh.12311
- Liu S, Watcha D, Holodniy M, et al. Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis. Ann Intern Med 2014;161(8):546-53. https://doi.org/10.7326/M14-0602
- Najafzadeh M, Andersson K, Shrank WH, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 2015;162(6):407-19. https://doi.org/10.7326/M14-1152
- Petta S, Cabibbo G, Enea M, et al. Cost-effectiveness of sofosbuvirbased triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2014;59(5):1692-705. https://doi.org/10.1002/hep.27010
- Pfeil AM, Reich O, Guerra IM, et al. Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in swiss patients with chronic hepatitis C. PLoS One 2015;10(5):e0126984. https://doi.org/10.1371/journal.pone.0126984
- Saab S, Gordon SC, Park H, et al. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther 2014;40(6):657-75. https://doi.org/10.1111/apt.12871
- Ke W, Zhang C, Liu L, et al. Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China. Hepatol Int 2016;10(6):924-36. https://doi.org/10.1007/s12072-016-9741-6
- Wu B, Li T, Chen H, et al. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis. Value Health 2010; 13(5):592-600. https://doi.org/10.1111/j.1524-4733.2010.00733.x
- Zhang C, Ke W, Gao Y, et al. Cost-effectiveness analysis of antiviral therapies for hepatitis B e antigen-positive chronic hepatitis B patients in China. Clin Drug Investig 2015;35(3):197-209. https://doi.org/10.1007/s40261-015-0273-y
- San Miguel R, Gimeno-Ballester V, Blazquez A, et al. Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. Gut 2015;64(8):1277-88. https://doi.org/10.1136/gutjnl-2014-307772
- Samsung Medical Center-Organ transplantation Center. FAQ-Cost for organ transplantation. Available from http://www.samsunghospital.com/dept/main/index.do?DP_CODE=OTC&MENU_ID= 007085160. Accessed January 16, 2018.
- Asan Medical Center-Organ Transplantation Center. Organ transplant procedure. Available from http://organ.amc.seoul.kr/asan/depts/organ/K/content.do?menuId=1610. Accessed January 16, 2018.
- Cruz RJ, Ranganathan S, Mazariegos G, et al. Analysis of national and single-center incidence and survival after liver transplantation for hepatoblastoma: New trends and future opportunities. Surgery 2013; 153(2):150-9. https://doi.org/10.1016/j.surg.2012.11.006
- Jain A, Reyes J, Kashyap R, et al. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 2000;232(4):490-500. https://doi.org/10.1097/00000658-200010000-00004
- Levy AR, Kowdley KV, Iloeje U, et al. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health 2008;11(3):527-38. https://doi.org/10.1111/j.1524-4733.2007.00297.x
- Sakata H, Tamura S, Sugawara Y, et al. Cost analysis of adult-adult living donor liver transplantation in Tokyo University Hospital. J Hepatobiliary Pancreat Sci 2011;18(2):184-9. https://doi.org/10.1007/s00534-010-0326-9
- Serper M, Bittermann T, Rossi M, et al. Functional status, healthcare utilization, and the costs of liver transplantation. Am J Transplant 2017. doi: 10.1111/ajt.14576. [Epub ahead of print]
- Thongsawat S, Piratvisuth T, Pramoolsinsap C, et al. Resource Utilization and Direct Medical Costs of Chronic Hepatitis C in Thailand: A Heavy but Manageable Economic Burden. Value in Health Regional Issues 2014;3:12-18. https://doi.org/10.1016/j.vhri.2013.09.002
- Kitazawa T, Matsumoto K, Fujita S, et al. Cost Analysis of Transplantation in Japan, Performed With the Use of the National Database. Transplant Proc 2017;49(1):4-9. https://doi.org/10.1016/j.transproceed.2016.10.007
- Lee H, Shin U, Lee C, et al. Medical Price Levels of OECD Countries: A Comparative Study: KMA Research Institute for Healthcare Policy, 2013. Available from http://www.dbpia.co.kr/Journal/ArticleDetail/NODE02467445. Accessed January 16, 2018.
- Abergel A, Rotily M, Branchoux S, et al. Chronic hepatitis C: Burden of disease and cost associated with hospitalisations in France in 2012 (The HEPC-LONE study). Clin Res Hepatol Gastroenterol 2016; 40(3):340-8. https://doi.org/10.1016/j.clinre.2015.08.006
- Kim Y, Shin S, Park J, et al. Costing methods in Healthcare: NECA, 2013. Available from https://www.neca.re.kr/lay1/bbs/S1T11C102/F/39/view.do?article_seq=5332&cpage=1&rows=10&condition=&keyword=&show=&cat=. Accessed January 16, 2018.
- Kim H-L, Park J-A, Sin J, et al. Analysis of Medical Use and Costs Related to the Management of Liver Cirrhosis Using National Patients Sample Data. Korean J Clin Pharm 2016;26(4):341-7.
- Shon C, Choi HY, Shim JJ, et al. The Economic Burden of Hepatitis A, B, and C in South Korea. Jpn J Infect Dis 2016;69(1):18-27. https://doi.org/10.7883/yoken.JJID.2014.499
- Chen GF, Wei L, Chen J, et al. Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data. PLoS One 2016; 11(6): e0155934. https://doi.org/10.1371/journal.pone.0155934
- Chhatwal J, He T, Hur C, et al. Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection are Cost Saving. Clin Gastroenterol Hepatol 2016;15(6):827-37. https://doi.org/10.1016/j.cgh.2016.09.015
- Virabhak S, Yasui K, Yamazaki K, et al. Cost-effectiveness of directacting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatmentnaive and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan. J Med Econ 2016:1-14.